Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Abbott

Is Abbott’s January Pullback a Good Time to Buy?

Abbott Laboratories' January price pullback is a signal to load up on shares; this Dividend Aristocrat is growing its business and driving cash flow.

MarketBeat

How Authentic Was Abbott Elementary In Relocating The Cast To An Abandoned Mall? Janelle James Opened Up About ‘Lots Of Smells’

At least the animatronic Ben Franklin head is dead!

Cinemablend

2 Healthcare Names That Could Get a Big Boost From Earnings

Both Abbott Laboratories and Intuitive Surgical report fourth-quarter results in late January—and both companies offer investors multiple reasons to be bullish.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Fortune 500 exec: College grads aren't ready for today's jobs

There's a missing link between college and career.

Fortune

With Abbott Elementary Nominated For Major Awards, The Stars Opened Up About Representing Traditional Sitcoms Against Streaming Competition

Will Abbott Elementary score in the awards circuit this year?

Cinemablend

This Dividend Stock Just Scored an FDA Win. Should You Buy Shares Now?

Abbott’s latest regulatory progress supports its durable growth narrative. Is now the right time to revisit ABT shares?

Barchart

Broadcom Just Raised Its Dividend—But It’s Not the Only One Signaling Strength

Broadcom, Abbott, and Nordic American raised dividends, offering strong yields and long-term upside despite market volatility and sector headwinds.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Abbott Elementary's Mid-Season Finale Featured Its Craziest Plot Twist, And I Can't Stop Thinking About The Silly Repercussions It Could Have

I cannot believe this really happened!

Cinemablend

FDA Warns Against Abbott Glucose Monitor Sensors After Reports Of Over 700 Injuries, 7 Deaths

The U.S. Food and Drug Administration (FDA) in December issued a safety alert urging people with diabetes to stop using select glucose sensors made by Abbott Laboratories’ (NYSE:ABT) Diabetes Care, after the company linked the devices to seven deaths and hundreds of serious injuries.

Benzinga

Faulty glucose monitors linked to 7 deaths and more than 700 injuries worldwide. Here’s what we know

The sensors provide real-time measurements of sugar levels in the blood, sending that data wirelessly to a device or phone.

Euronews

Faulty glucose monitors linked to 7 deaths and more than 700 injuries, FDA warns

The U.S. Food and Drug Administration warned people to stop using certain types of glucose monitor sensors that were linked to seven deaths

The Independent UK

7 deaths linked to faulty glucose monitors put in people’s arms, FDA says

About three million devices are affected, though many may be expired or already used

The Independent UK

Is Abbott Laboratories Stock Underperforming the S&P 500?

Abbott Laboratories has lagged behind the S&P 500 in recent months as well as over the past year, yet analysts remain strongly bullish on the stock’s prospects.

Barchart

How This 'Hidden Gold Mine' Has Beaten The Market For 30 Years

For three decades, I have watched investors chase the latest hot stock, the newest tech darling, and the most hyped IPO. Meanwhile, a sleepy corner of the market has been quietly minting fortunes.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Deal Dispatch: Abbott, TPG And Lonza Make Major Moves, M&M Custard And New Fortress Energy Struggle

For the previous edition of Deal Dispatch, click here.

Woman & Home

Our fashion team has been hunting Black Friday fashion deals for years – here are the 24 items we really rate

Plenty of brands have already dropped major Black Friday discounts, and these are items worth shopping right now

Barchart

Exact Sciences Stock Pops on $21 Billion Deal. Is It Too Late to Buy EXAS Here?

Exact Sciences stock rallies as Abbott announces a $21 billion deal to acquire to the molecular diagnostics firm. Here’s why EXAS shares are unlikely to push any higher in 2026.

International Business Times UK

Abbott-Exact Sciences Deal Set to Shake Up Diagnostic Market with Cancer-Fighting Acquisition

Rumours fly that Abbott is very close to sealing the deal to acquire cancer treatment champion Exact Sciences.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics

Abbott Laboratories (NYSE:ABT) agreed on Thursday to acquire cancer screening company Exact Sciences Corp (NASDAQ:EXAS) for $105 per common share, representing a total equity value of approximately $21 billion and an estimated enterprise value of $23 billion.

Cinemablend

The Paper Is A Blast, And I Want A Specific Crossover With Abbott Elementary

Hear me out.

Benzinga

The Insider Report: The Bears Have Been Poked – Will They Fall Back Asleep?

Stocks dropped hard last week, but a late-day rally on Friday staved off the worst. The Dow Jones Industrial Average held up the best, only closing down 1.21%. The SP 500 was down 1.63%, but the Nasdaq suffered the most, as it closed down 3.04%. Tech was routed hard as…

The Independent UK

Preliminary tests find germ that causes botulism in ByHeart baby formula

California health officials say tests showed that ByHeart baby formula linked to a botulism outbreak contained the type of bacteria that produces the toxin that has sickened at least 13 infants in 10 states

Barchart

Abbott Laboratories Stock Outlook: Is Wall Street Bullish or Bearish?

Despite underperforming the broader market over the past year, Wall Street analysts remain highly bullish on Abbott Laboratories' long-term outlook.

Barchart

5 Dividend Aristocrats Proving That Reliability Still Pays in 2025

These five companies offer stability in terms of growth and income.

MarketBeat

Abbott Laboratories' October Price Plunge Is a Signal to Buy

Abbott Laboratories is on track to reach new highs, potentially by early 2026, opening the door for a 30% stock price increase in addition to the dividend.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.